Pulse Biosciences, Inc

PLSE Healthcare Medical Instruments & Supplies

Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022.

Revenue
+359.3%
EPS
−10.3%
Free cash flow
−1,180.5%

Quarter to September 2026, against a year earlier

53.15 3.91 −6.85%
Market cap
$3.9B
P/E
0.0×
Fwd P/E
−38.1×
Dividend yield
—
F-score
n/a
Altman Z
31.41
Beneish M
n/a
Dividend safety
n/a

Pulse Biosciences, Inc (PLSE) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Pulse Biosciences, Inc (PLSE) trades at a P/S ratio of 2,559×. Over the past ten years it has ranged from 0.0× (June 2022) to 3,223× (September 2026); the current reading is higher than 98% of that period. That is above the Medical Instruments & Supplies industry median of 2.5× and above the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 1,527× 2,426.34%
FY2022 60.4× —
FY2021 0.0× —

Quarterly newest first

Period P/S ratio Change
Sep 2026 2,403× 48.42%
Jun 2026 1,619× (18.15%)
Mar 2026 1,978× 29.57%
Dec 2025 1,527× 0.63%
6 more quarters

Against its own ten years

Low 0.0× High 3,223×
Ten-year median 0.0×
Current reading's percentile 96

P/S ratio against peers

Company P/S ratio
NVST Envista Holdings Corporation compare 1.4×
MMED MiniMed Group, Inc. compare 1.7×
ICUI ICU Medical, Inc. compare 1.9×
STVN Stevanato Group S.p.A. compare 2.5×
TFX Teleflex Incorporated compare 2.9×
MMSI Merit Medical Systems, Inc. compare 3.3×
WRBY Warby Parker Inc. compare 3.5×
ATRC AtriCure, Inc. compare 5.0×
PLSE Pulse Biosciences, Inc 2,559×
Medical Instruments & Supplies industry median 2.5×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on PLSE